mRNA-LNP
Vaccine Development
At Helix Biotech, we are at the forefront of mRNA-LNP vaccine development, leveraging cutting-edge lipid nanoparticle (LNP) technology to revolutionize the way vaccines are formulated, manufactured, and delivered. Starting from sequence, we help with the synthesis and manufacturing of all components of nucleic-acid based vaccines.
​NIH Vaccine Repository
Helix Biotech’s vaccine biosimilars are not only developed to the highest standards but are also supplied to the NIH BEI Resources Repository. This underscores the trust in our products and their pivotal role in advancing vaccine research and global health initiatives.
​
Proven Performance in Vaccine Development
Data provided by
Dr. Debbie Burnett
mRNA-LNP Vaccines produced by the Helix Biotech and our patented Nova™ system can achieve immunogenicity profiles comparable to or better than those of leading commercial vaccines.
Product Citations
-
Alexander A. Cohen, Jennifer R. Keeffe, ... Pamela J. Bjorkman et al. "Mosaic sarbecovirus nanoparticles elicit cross-reactive responses in pre-vaccinated animals." Cell. 187, 20. 2024.
-
Eric Wang, Alexander A. Cohen, Jennifer R. Keeffe, ... Pamela J. Bjorkman, Arup K. Chakraborty et al. "Designed mosaic nanoparticles enhance cross-reactive immune responses in mice." Cell. 188, 4. 2025.
-
Jian Hang Lam, ... Madhavan Nallani et al. "Development of Thermostable and Immunogenic Block Copolymer Nanoparticles (BNPs) for mRNA Delivery." Biomacromolecules. 2025.
-
Alexander A. Cohen, Jennifer R. Keeffe, ... Pamela J. Bjorkman et al. "Single administration of mosaic-8b RBD-nanoparticle vaccine prepared with atomic layer deposition technology elicits broadly neutralizing anti-sarbecovirus responses." bioRxiv. Preprint. 2025.
What are the key steps in vaccine development?
(1) Antigen Selection and mRNA Design
(2) mRNA IVT Synthesis
(3) LNP Formulation and Optimization
(4) Analytical Testing and Method Development
(5) In Vivo Testing
​
